A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF REPEATED ADMINISTRATIONS OF NUROWN® (AUTOLOGOUS MESENCHYMAL STEM CELLS SECRETING NEUROTROPHIC FACTORS) IN PARTICIPANTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)

2017-3818
NCT03280056
Cancer - Other
Namita Goyal
Open
INT - Drug
III
Adult
National

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.